Company Description
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany.
The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.
Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients.
The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists.
The company was incorporated in 2007 and is based in Redwood City, California.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jan 30, 2015 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 72 |
| CEO | Jeffrey Soinski |
Contact Details
Address: 400 Chesapeake Drive Redwood City, California 94063 United States | |
| Phone | 650 241 7900 |
| Website | avinger.com |
Stock Details
| Ticker Symbol | AVGR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001506928 |
| CUSIP Number | 053734604 |
| ISIN Number | US0537348775 |
| Employer ID | 20-8873453 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Himanshu N. Patel | Chief Technology Officer |
| Keith Schaefer | Chief Operating Officer |
| Philip R. Preuss | Chief Commercial Officer |
| Dr. Jaafer Golzar FACC, M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2025 | DEFR14A | Filing |
| Jan 13, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 3, 2025 | 8-K | Current Report |
| Jan 2, 2025 | 8-K | Current Report |
| Dec 23, 2024 | DEF 14A | Other definitive proxy statements |
| Dec 19, 2024 | 8-K | Current Report |
| Dec 13, 2024 | 8-K | Current Report |
| Dec 11, 2024 | 8-K | Current Report |
| Dec 11, 2024 | PRE 14A | Other preliminary proxy statements |
| Nov 22, 2024 | 8-K | Current Report |